Barriers for access to new medicines : searching for the balance between rising costs and limited budgets

2018
journal article
review article
104
cris.lastimport.wos2024-04-10T03:16:13Z
dc.abstract.enIntroduction: There is continued unmet medical need for new medicines across countries especially for cancer, immunological diseases, and orphan diseases. However, there are growing challenges with funding new medicines at ever increasing prices along with funding increased medicine volumes with the growth in both infectious diseases and non-communicable diseases across countries. This has resulted in the development of new models to better manage the entry of new medicines, new financial models being postulated to finance new medicines as well as strategies to improve prescribing efficiency. However, more needs to be done. Consequently, the primary aim of this paper is to consider potential ways to optimize the use of new medicines balancing rising costs with increasing budgetary pressures to stimulate debate especially from a payer perspective. Methods: A narrative review of pharmaceutical policies and implications, as well as possible developments, based on key publications and initiatives known to the co-authors principally from a health authority perspective. Results: A number of initiatives and approaches have been identified including new models to better manage the entry of new medicines based on three pillars (pre-, peri-, and post-launch activities). Within this, we see the growing role of horizon scanning activities starting up to 36 months before launch, managed entry agreements and post launch follow-up. It is also likely there will be greater scrutiny over the effectiveness and value of new cancer medicines given ever increasing prices. This could include establishing minimum effectiveness targets for premium pricing along with re-evaluating prices as more medicines for cancer lose their patent. There will also be a greater involvement of patients especially with orphan diseases. New initiatives could include a greater role of multicriteria decision analysis, as well as looking at the potential for de-linking research and development from commercial activities to enhance affordability. Conclusion: There are a number of ongoing activities across countries to try and fund new valued medicines whilst attaining or maintaining universal healthcare. Such activities will grow with increasing resource pressures and continued unmet need.pl
dc.affiliationWydział Nauk o Zdrowiu : Instytut Zdrowia Publicznegopl
dc.cm.date2020-01-07
dc.cm.id92368
dc.contributor.authorGodman, Brianpl
dc.contributor.authorBucsics, Annapl
dc.contributor.authorVella Bonanno, Patriciapl
dc.contributor.authorOortwijn, Wijapl
dc.contributor.authorRothe, Celia C.pl
dc.contributor.authorFerrario, Alessandrapl
dc.contributor.authorBossell, Simonepl
dc.contributor.authorHill, Andrewpl
dc.contributor.authorMartin, Antony P.pl
dc.contributor.authorSimoens, Stevenpl
dc.contributor.authorKurdi, Amanjpl
dc.contributor.authorGad, Mohamedpl
dc.contributor.authorGulbinovic, Jolantapl
dc.contributor.authorTimoney, Angelapl
dc.contributor.authorBochenek, Tomasz - 128800 pl
dc.contributor.authorSalem, Ahmedpl
dc.contributor.authorHoxha, Irispl
dc.contributor.authorSauermann, Robertpl
dc.contributor.authorMassele, Amospl
dc.contributor.authorGuerra Jr., Augusto Alfonsopl
dc.contributor.authorPetrova, Guenkapl
dc.contributor.authorMitkova, Zornitsapl
dc.contributor.authorAchniotou, Gnosiapl
dc.contributor.authorLaius, Ottpl
dc.contributor.authorSermet, Catherinepl
dc.contributor.authorSelke, Gisbertpl
dc.contributor.authorKourafalos, Vasileiospl
dc.contributor.authorYfantopoulos, Johnpl
dc.contributor.authorMagnusson, Einarpl
dc.contributor.authorJoppi, Robertapl
dc.contributor.authorOluka, Margaretpl
dc.contributor.authorKwon, Hye-Youngpl
dc.contributor.authorJakupi, Arianitpl
dc.contributor.authorKalemeera, Francispl
dc.contributor.authorFadare, Joseph O.pl
dc.contributor.authorMellen, Oyvindpl
dc.contributor.authorPomorski, Maciejpl
dc.contributor.authorWladysiuk, Magdalenepl
dc.contributor.authorMarkovic-Pekovic, Vandapl
dc.contributor.authorMardare, Ileanapl
dc.contributor.authorMeshkov, Dimitrypl
dc.contributor.authorNovakovic, Tanjapl
dc.contributor.authorFurst, Jurijpl
dc.contributor.authorTomek, Dominikpl
dc.contributor.authorZara, Corinepl
dc.contributor.authorDiogene, Eduardopl
dc.contributor.authorMeyer, Johanna C.pl
dc.contributor.authorMalmstrom, Rickard E.pl
dc.contributor.authorWattermark, Bjornpl
dc.contributor.authorMatsebula, Zinhlepl
dc.contributor.authorCampbell, Stephenpl
dc.contributor.authorHaycox, Alanpl
dc.date.accessioned2020-01-17T10:02:55Z
dc.date.available2020-01-17T10:02:55Z
dc.date.issued2018pl
dc.date.openaccess0
dc.description.accesstimew momencie opublikowania
dc.description.points15pl
dc.description.publication2,52pl
dc.description.versionostateczna wersja wydawcy
dc.description.volume6pl
dc.identifier.articleid328pl
dc.identifier.doi10.3389/fpubh.2018.00328pl
dc.identifier.eissn2296-2565
dc.identifier.projectROD UJ / OPpl
dc.identifier.urihttps://ruj.uj.edu.pl/xmlui/handle/item/144933
dc.languageengpl
dc.language.containerengpl
dc.rightsUdzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa*
dc.rights.licenceCC-BY
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/legalcode.pl*
dc.share.typeotwarte czasopismo
dc.subject.enmanaged entrypl
dc.subject.enhealth policypl
dc.subject.enpharmaceuticalspl
dc.subject.enfinancingpl
dc.subject.encancerpl
dc.subject.enorphan diseasespl
dc.subject.ennew modelspl
dc.subtypeReviewArticlepl
dc.titleBarriers for access to new medicines : searching for the balance between rising costs and limited budgetspl
dc.title.journalFrontiers in Public Healthpl
dc.typeJournalArticlepl
dspace.entity.typePublication
cris.lastimport.wos
2024-04-10T03:16:13Z
dc.abstract.enpl
Introduction: There is continued unmet medical need for new medicines across countries especially for cancer, immunological diseases, and orphan diseases. However, there are growing challenges with funding new medicines at ever increasing prices along with funding increased medicine volumes with the growth in both infectious diseases and non-communicable diseases across countries. This has resulted in the development of new models to better manage the entry of new medicines, new financial models being postulated to finance new medicines as well as strategies to improve prescribing efficiency. However, more needs to be done. Consequently, the primary aim of this paper is to consider potential ways to optimize the use of new medicines balancing rising costs with increasing budgetary pressures to stimulate debate especially from a payer perspective. Methods: A narrative review of pharmaceutical policies and implications, as well as possible developments, based on key publications and initiatives known to the co-authors principally from a health authority perspective. Results: A number of initiatives and approaches have been identified including new models to better manage the entry of new medicines based on three pillars (pre-, peri-, and post-launch activities). Within this, we see the growing role of horizon scanning activities starting up to 36 months before launch, managed entry agreements and post launch follow-up. It is also likely there will be greater scrutiny over the effectiveness and value of new cancer medicines given ever increasing prices. This could include establishing minimum effectiveness targets for premium pricing along with re-evaluating prices as more medicines for cancer lose their patent. There will also be a greater involvement of patients especially with orphan diseases. New initiatives could include a greater role of multicriteria decision analysis, as well as looking at the potential for de-linking research and development from commercial activities to enhance affordability. Conclusion: There are a number of ongoing activities across countries to try and fund new valued medicines whilst attaining or maintaining universal healthcare. Such activities will grow with increasing resource pressures and continued unmet need.
dc.affiliationpl
Wydział Nauk o Zdrowiu : Instytut Zdrowia Publicznego
dc.cm.date
2020-01-07
dc.cm.id
92368
dc.contributor.authorpl
Godman, Brian
dc.contributor.authorpl
Bucsics, Anna
dc.contributor.authorpl
Vella Bonanno, Patricia
dc.contributor.authorpl
Oortwijn, Wija
dc.contributor.authorpl
Rothe, Celia C.
dc.contributor.authorpl
Ferrario, Alessandra
dc.contributor.authorpl
Bossell, Simone
dc.contributor.authorpl
Hill, Andrew
dc.contributor.authorpl
Martin, Antony P.
dc.contributor.authorpl
Simoens, Steven
dc.contributor.authorpl
Kurdi, Amanj
dc.contributor.authorpl
Gad, Mohamed
dc.contributor.authorpl
Gulbinovic, Jolanta
dc.contributor.authorpl
Timoney, Angela
dc.contributor.authorpl
Bochenek, Tomasz - 128800
dc.contributor.authorpl
Salem, Ahmed
dc.contributor.authorpl
Hoxha, Iris
dc.contributor.authorpl
Sauermann, Robert
dc.contributor.authorpl
Massele, Amos
dc.contributor.authorpl
Guerra Jr., Augusto Alfonso
dc.contributor.authorpl
Petrova, Guenka
dc.contributor.authorpl
Mitkova, Zornitsa
dc.contributor.authorpl
Achniotou, Gnosia
dc.contributor.authorpl
Laius, Ott
dc.contributor.authorpl
Sermet, Catherine
dc.contributor.authorpl
Selke, Gisbert
dc.contributor.authorpl
Kourafalos, Vasileios
dc.contributor.authorpl
Yfantopoulos, John
dc.contributor.authorpl
Magnusson, Einar
dc.contributor.authorpl
Joppi, Roberta
dc.contributor.authorpl
Oluka, Margaret
dc.contributor.authorpl
Kwon, Hye-Young
dc.contributor.authorpl
Jakupi, Arianit
dc.contributor.authorpl
Kalemeera, Francis
dc.contributor.authorpl
Fadare, Joseph O.
dc.contributor.authorpl
Mellen, Oyvind
dc.contributor.authorpl
Pomorski, Maciej
dc.contributor.authorpl
Wladysiuk, Magdalene
dc.contributor.authorpl
Markovic-Pekovic, Vanda
dc.contributor.authorpl
Mardare, Ileana
dc.contributor.authorpl
Meshkov, Dimitry
dc.contributor.authorpl
Novakovic, Tanja
dc.contributor.authorpl
Furst, Jurij
dc.contributor.authorpl
Tomek, Dominik
dc.contributor.authorpl
Zara, Corine
dc.contributor.authorpl
Diogene, Eduardo
dc.contributor.authorpl
Meyer, Johanna C.
dc.contributor.authorpl
Malmstrom, Rickard E.
dc.contributor.authorpl
Wattermark, Bjorn
dc.contributor.authorpl
Matsebula, Zinhle
dc.contributor.authorpl
Campbell, Stephen
dc.contributor.authorpl
Haycox, Alan
dc.date.accessioned
2020-01-17T10:02:55Z
dc.date.available
2020-01-17T10:02:55Z
dc.date.issuedpl
2018
dc.date.openaccess
0
dc.description.accesstime
w momencie opublikowania
dc.description.pointspl
15
dc.description.publicationpl
2,52
dc.description.version
ostateczna wersja wydawcy
dc.description.volumepl
6
dc.identifier.articleidpl
328
dc.identifier.doipl
10.3389/fpubh.2018.00328
dc.identifier.eissn
2296-2565
dc.identifier.projectpl
ROD UJ / OP
dc.identifier.uri
https://ruj.uj.edu.pl/xmlui/handle/item/144933
dc.languagepl
eng
dc.language.containerpl
eng
dc.rights*
Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa
dc.rights.licence
CC-BY
dc.rights.uri*
http://creativecommons.org/licenses/by/4.0/legalcode.pl
dc.share.type
otwarte czasopismo
dc.subject.enpl
managed entry
dc.subject.enpl
health policy
dc.subject.enpl
pharmaceuticals
dc.subject.enpl
financing
dc.subject.enpl
cancer
dc.subject.enpl
orphan diseases
dc.subject.enpl
new models
dc.subtypepl
ReviewArticle
dc.titlepl
Barriers for access to new medicines : searching for the balance between rising costs and limited budgets
dc.title.journalpl
Frontiers in Public Health
dc.typepl
JournalArticle
dspace.entity.type
Publication
Affiliations

* The migration of download and view statistics prior to the date of April 8, 2024 is in progress.

Views
14
Views per month
Views per city
Ashburn
2
Tower Hamlets
2
Wroclaw
2
Des Moines
1
Dublin
1
Miękinia
1
Montreal
1
Szczecin
1
Downloads
bochenek_et-al_barriers_for_access_to_new_medicines_2018.pdf
8